

Slide
1

CLINICAL TRIAL SIMULATION & ANALYSIS

Nick Holford
Dept Pharmacology & Clinical Pharmacology
University of Auckland, New Zealand

©NHG Holford, 2016, all rights reserved.

Slide
2

SIMULATION

- Visualise the expected results
- Plan data layout
- Rehearse analysis method
- Optimise design

©NHG Holford, 2016, all rights reserved.

Slide
3

Pharmacometric Tools

- Simulation
 - Excel
 - Berkeley Madonna
 - Pharsight Trial Simulator
- Individual Non-Linear Regression
 - WinNonLin / Adapt/Kinetica
- Population Non-Linear Regression
 - NONMEM / Monolix/Phoenix

©NHG Holford, 2016, all rights reserved.

Slide
4

Using Simulation To Understand Dose, Concentration or AUC?

- Why use Dose?
 - Direct translation to prescription
- Why not use Dose?
 - Ignores individual differences

©MKG Hallford, 2018, all rights reserved.

Slide
5

Dose, Concentration or AUC?

- Why use Concentration?
 - Learn about time course
 - Account for individual PK differences
- Why not use Concentration?
 - May be hard to measure
 - Extra resources for PK analysis

©MKG Hallford, 2018, all rights reserved.

Slide
6

Dose, Concentration or AUC?

- Why use AUC?
 - Account for individual PK differences
- Why not use AUC?
 - May be hard to measure
 - Extra resources for PK analysis
 - Ignores time course

©MKG Hallford, 2018, all rights reserved.

Slide
7


When is Time Course Important?

- Dose vs AUC is linear
 - C vs Effect is non-linear
 - Outcome is related to cumulative effect
- Almost all drugs!**

©NHG Holland, 2015, all rights reserved.

Slide
8


Frusemide Diuretic Effect



©NHG Holland, 2015, all rights reserved.

Slide
9


Frusemide Diuretic Effect



©NHG Holland, 2015, all rights reserved.

Slide 10


Frusemide Diuretic Effect



©HGS Hallford, 2018, all rights reserved.

Slide 11

Frusemide Response



©HGS Hallford, 2018, all rights reserved.

Slide 12

What Questions does CTS help to Answer?

- **Learning Trials**
 - How big an effect?
 - Effect Size Estimates
 - **Bias and Precision**
- **Confirming Trials**
 - Does the drug work?
 - YES/NO Answer
 - **Power**

©HGS Hallford, 2018, all rights reserved.

Slide
13

Simulation Models

- Covariate Distribution
 - Variability and covariance
 - Predicts Subject characteristics (age, weight, sex, renal function)
- Input-Output
 - Structural, fixed and random effects
 - Predicts protocol observations
- Execution
 - Deviations from nominal protocol
 - Predicts actual observations

©NHG Holland, 2012, all rights reserved.

Slide
14

Exposure-Response Relationship

- Exposure
 - Dose
 - Area under the Conc-Time Curve
 - Concentration(Time)
- Response
 - Biomarker
 - Clinical Outcome

©NHG Holland, 2012, all rights reserved.

Slide
15

Clinical Trial Simulation (CTS) Process

1. Predict time course of response in patient
2. Add variability (subject, execution)
3. Analyse single clinical trial
4. Replicate Steps 1-3 multiple times (100+)
5. Meta-analysis of multiple replicates
6. Evaluate design performance (e.g. power)
7. Replicate Steps 4-6 over design space
8. Construct design-performance surface

©NHG Holland, 2012, all rights reserved.

Slide
16

Monte-Carlo Simulation

- Developed for atomic bomb research
- Based on using random numbers to generate simulated data
- Very powerful tool for modern statistics

©NHG Holland, 2012, all rights reserved.

Slide
17


Why Use Simulation for Exposure Response?

- **Between subject variability**
 - Covariate Distribution model
- **Complex time varying responses**
 - Input Output model
- **Nominal protocol never happens**
 - Execution model

©NHG Holland, 2012, all rights reserved.


Slide
18

Exposure Response Shape



©NHG Holland, 2012, all rights reserved.

Slide 19



Slide 20

Parameter Sensitivity

- Always uncertainty about key parameters
- Consider two cases compared to existing therapy:
 - **Standard**: New drug similar Emax
 - **Super**: New drug has greater Emax

©HGS Hallford, 2018, all rights reserved.

Slide 21

Does The Drug Work?

Power to Detect One or More Significant Dose Levels

Assumption	No Effect	Lin	Emax	SEmax	Ushape
Slow Std		63	53	80	21
Fast Std		97	97	100	69
Slow Super		97	98	100	62
Fast Super	1	100	100	100	100

- Sensitive to magnitude of effect
- Poor power for slow onset
- Poor power for U Shape DR pattern
- Type 1 error (no effect column) is acceptable (1%)

©HGS Hallford, 2018, all rights reserved.

Slide
22

How Big an Effect?

Estimation Bias in Size of Treatment Effect

DR Pattern	Best effect dose	Standard		Super	
		slow onset	fast onset	slow onset	fast onset
Linear	25	45	98	46	98
SEMax	25	68	103	68	104
E _{max}	25	49	91	50	92
Ushape	10	39	99	41	100

% of true value at 2 weeks for best effect dose

- Slow onset has **biased** (under) estimate of true treatment effect

©NHG Holland, 2018. all rights reserved.

Slide
23

Conclusion Why Do Simulation?

- Deterministic
 - Complex questions
 - Often simple graphs (e.g. frusemide)
- Stochastic
 - To answer a statistical question
 - Power, Precision

©NHG Holland, 2018. all rights reserved.

Slide
24

©NHG Holland, 2018. all rights reserved.

Slide
25

ANALYSIS

- Descriptive
- Comparison
 - Means
 - Proportions
- Regression
 - Linear
 - Non-linear

©2008 Pearson Education, Inc. All rights reserved.

Slide
26

Descriptive Statistics

- Mean
- Standard Deviation
- Standard Error
- etc

©2008 Pearson Education, Inc. All rights reserved.

Slide
27

Means

- Two Samples
 - t-test
- ANOVA
 - one factor
 - two factor
 - etc
- Parametric/Non-Parametric
- Repeated Measures

©2008 Pearson Education, Inc. All rights reserved.

Slide
28

Proportions

- Chi-square

©HSG Holland, 2018, all rights reserved.

Slide
29

Regression

- Correlation
- Linear regression
 - simple
 - multiple
- Non-linear regression
 - individual
 - population

©HSG Holland, 2018, all rights reserved.

Slide
30

Regression

- Parameters and Models
 - Test hypotheses with different models
 - Estimate parameters

©HSG Holland, 2018, all rights reserved.